Companies

BIA Separations is the leading developer and manufacturer of CIM® (Convective Interaction Media) monolithic chromatographic columns intended for production, purification and analytics of large biomolecules. The company has its headquarters in Austria, a research and production facility in Slovenia, and sales offices in the US and China. The mission of the company is to develop and produce CIM® monolithic columns

ChiPro GmbH, founded 1999 is a multi-profile enterprise offering client-specifiic services in the Life Sciences sector. We develop natural and eco-friendly products in different fields. ChiPro has since its beginning intensive cooperation with mainly Asian partners. Growth happens more in participation on new or partner companies than with own staff.

lcosagen Group (formerly Quattromed Group) comprises the leading biotechnology group in Estonia. lcosagen Group comprises lcosagen Cell Factory OÜ, a technology development company dedicated to the development of the portfolio of QMCF technology-based applications and contract services on production of biological substances (recombinant proteins, antibodies and virus like particles. lcosagen AS, producing and marketing natural rubber allergen tests (FITkit®) and life science products such as monoclonal antibodies, enzymes etc.

Proxcys B.V. is an independent privately owned company (SME) with a prime focus towards the development of high performance Downstream Processing technology. One of the main products is the HP-RFC (High Performance Radial Flow Chromatography) technology including equipment to operate, resin handling and optimization studies. New developments include SUPR columns, disposable technology capable of reaching a single column volume of 375 L, which is not achievable in the traditional axial format.

lnfoConsult was founded in 1997 and is specialized in all areas of innovation management especially for SME and public bodies. Regarding International projects, they give support in definition and financing of innovations and new products. They help their customers to acquire public funding on the local, national, and international level. In this branch, reference customers are the University of Bremen and affiliated institutions, Bremen ministries and European industrial companies. They deal with quality management in RTD and with preparation of the market entry of new products

Biomedal S.L. is a biotechnology company founded in 2000 with 22 employees, whose mission is to develop and commercialize new technologies, services and products for research, bio-industry and diagnostics. Biomedal enhances the talent of its team with the collaboration of an outstanding and growing network of international scientists and technologists, and directs its efforts to satisfy its customers.

VirtuaiPie limited is a consultancy and research company specialising in fluid dynamics consultancy to a wide range of industries it is the SME owner of BHR Group, which was founded in to 1947 to develop industrial knowledge and technologies in the field of fluid mechanics and dynamics. It has been at the forefront of research and development in the field of mixing for over 35 years and specialises in developing experimentally validated scale up correlations for all industries and all forms of mixing, reaction engineering and separation technologies. Since the early 90’s it has developed extensive engineering design, simulation and process intensification knowhow in respect of production of novel products including nanoparticles using compact micro reactors and processing equipment. The organization has also developed specialised techniques for complex measurement and modelling of combined mixing and reaction processes including complex rheological materials, powder wetting and drawdown and nanoparticle dispersion. BHR also has extensive computational fluid dynamics and other simulation/analytical mathematical capabilities with validated models for many mixing and reaction scenarios as well as memb.rane flux etc.

ZIP Solutions S.L. is a Biotech SME, developing breakthrough proprietary technologies for the production and purification of recombinant proteins.
The company acquired and further developed robust technological platforms that have been widely validated for their efficacy at an initial stage and focuses on their commercial exploitation, both through co-development with customers and through the out-licensing of owned intellectual property.

GENERI BIOTECH is a biotech SME, founded 1995, with expertise in molecular biology, i.e., sequencing, molecular cloning, cell cultures, analysis of gene expression via DNA arrays or real-time PCR, design/development of real-time PCR systems, oligonucleotide based therapeutics development/testing, RNA interference, genetic modification of eukaryotic cell lines, production of recombinant proteins in eukaryotic systems. GENERI BIOTECH has certified laboratories, including research, according to IS09001:2000 quality standards. It has more than 15 years of experience with mammalian cell-line maintenance and genetic modifications. It is producing recombinant proteins in eukaryotic cells for more than 10 years.

ethris GmbH develops innovative therapeutics based on proprietary platform technologies with high diversification potential that enable therapies for diseases with currently dissatisfying treatment options. SNIM® RNA is a first-in-class biopharmaceutical platform for therapies of rare diseases, replacement of recombinant proteins, and for “Transcript Therapies” in regenerative medicine. ethris enabling therapies provide access to highly profitable markets. ethris was founded at the end of 2009 by PD Dr. Carsten Rudolph (CEO) and Prof. Dr. Christian Plank (CSO) and was later joined by Dr. Walter Schmidt. The goal of ethris is to rapidly and continuously translate its world-wide unique expertise into clinical trials.